Effect of route of EPO administration on hemodialysis arteriovenous vascular access failure: a randomized controlled trial

• Published in: American journal of kidney diseases Vol. 53; no. 5; p. 815
• Main Authors: Lee, Young-Ki, Koo, Ja-Ryong, Kim, Jin-Kyung, Park, In-Il, Joo, Min-Ha, Yoon, Jong-Woo, Noh, Jung-Woo, Vaziri, Nosratola D
• Format: Journal Article
• Language: English
• Published: United States 01.05.2009
• Subjects: Catheters, Indwelling; Drug Administration Routes; Equipment Failure; Erythropoietin - administration & dosage; Erythropoietin - adverse effects; Female; Follow-Up Studies; Humans; Injections, Intravenous; Injections, Subcutaneous; Inpatients; Kidney Failure, Chronic - therapy; Korea - epidemiology; Male; Middle Aged; Morbidity - trends; Recombinant Proteins; Renal Dialysis - methods; Retrospective Studies; Risk Factors; Thrombosis - epidemiology; Thrombosis - etiology; Thrombosis - prevention & control; Time Factors; Treatment Outcome; Korea

Vascular access failure is a major cause of morbidity and hospitalization in hemodialysis populations worldwide. Erythropoietin (EPO) potentially can contribute to vascular access stenosis and occlusion by promoting intimal hyperplasia and thrombosis. Intravenous administration of EPO results in a s...